Effect of hydroquinone 4% topical cream versus glucosamine 2% topical cream on treatment of melasma

Effect of hydroquinone 4% topical cream versus glucosamine 2% topical cream on treatment of melasma: a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N399

Enrollment

Registered

2021-06-21

Start date

2021-07-06

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma. Chloasma

Interventions

Intervention 1: Intervention group 1: Hydroquinone 4% topical cream (manufactured by Behvarzan Pharmaceutical Co.) once every night for 8 weeks plus SFP50 sunscreen (manufactured by Dr. Jila Pharmaceu

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 65 years; Existence of mild melasma symmetrically on both sides of the face;

Exclusion criteria

Exclusion criteria: Pregnancy; Existence of other skin diseases; History of skin laser-therapy; Using sunscreen; Allergy to hydroquinone or glucosamine

Design outcomes

Primary

Measure	Time frame
Lesion size. Timepoint: Before the intervention and 2, 4, 6 and 8 weeks after that. Method of measurement: By photography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Behnam Moafi

Hamedan University of Medical Sciences

dr.behnammoafi@yahoo.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026